Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety.

NCT04730895 is registered in ClinicalTrials.gov with Kafrelsheikh University as lead sponsor.

NCT NCT04730895
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04730895 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety.
Lead sponsor
Kafrelsheikh University
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 31, 2021
Completion date
December 31, 2023
Enrollment
360 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid19 vaccine